李紀(jì)良（腫瘤轉(zhuǎn)化醫(yī)學(xué)中心）

個(gè)人簡(jiǎn)介

李紀(jì)良 (JILIANG LI, MMed, PhD)，系英國(guó)倫敦大學(xué)博士、牛津大學(xué)博士后、Imperial Cancer Research Fund (ICRF) Fellow、Cancer Research UK (CRUK)/牛津大學(xué)終身科學(xué)家、英國(guó)著名大學(xué)醫(yī)學(xué)院腫瘤學(xué)終身教授/主任、浙江省特聘專家、中國(guó)科學(xué)院大學(xué)溫州研究院兼職教授、腫瘤轉(zhuǎn)化醫(yī)學(xué)中心負(fù)責(zé)人。承擔(dān)、參與和完成多項(xiàng)重大腫瘤科技項(xiàng)目，多次受邀在國(guó)際學(xué)術(shù)會(huì)議上作大會(huì)報(bào)告，并在Cancer Cell、Cell Metabolism、Hepatology、Blood、Nature Commun、PNAS和Cancer Research為代表的多種國(guó)際專業(yè)主流期刊上發(fā)表SCI論文90多篇。其論文被包括Nature、Science和Cell等在內(nèi)的著名專業(yè)雜志引用9000多次 (按Google Scholar檢索)，期中最高單篇論文被引>940多次，單篇論文被引>100次的有28篇，H-因子48。擔(dān)任American Journal of Cancer Research等10余家國(guó)際學(xué)術(shù)雜志編委。擔(dān)任英國(guó)、德國(guó)、法國(guó)、荷蘭、新西蘭、新加坡等眾多國(guó)家基金項(xiàng)目特邀評(píng)審專家及Nature Commun、Hepatology、Gut、Blood、PNAS、Cancer Research、Clinical Cancer Research和Journal of Pathology等40多家國(guó)際專業(yè)性雜志評(píng)審專家。在腫瘤學(xué)相關(guān)領(lǐng)域內(nèi)享有較高的學(xué)術(shù)聲譽(yù)，兩次受Cancer Cell 雜志社特邀對(duì)發(fā)表于該刊當(dāng)期最新論文撰寫述評(píng)，并受雜志社特邀對(duì)最新Nature論文撰寫述評(píng)。

研究領(lǐng)域

Our research interest focuses on tumour microenvironment and translational cancer medicine. By employing a variety of approaches including molecular and cellular biology, immunology, proteomics, single cell sequencing, bioinformatics, animal pre-clinical models, and human tumour samples, our research is dedicated to delineate mechanisms on how key molecules (such as microRNAs, lncRNAs, and RNF181 E3 ligase), signalling pathways (such as Notch signalling), tumour cells, and tumour stromal cells (such as endothelial cells, infiltrated lymphocytes, tumour-associated macrophages, and tumour-associated fibroblasts) in tumour microenvironment regulate tumour growth, invasion and metastasis, and tumour response to standard therapeutic interventions (in particular, cross-interactions among radiotherapy, chemotherapy, targeted therapy or immunotherapy). Our aims are (1) to dissect mechanisms of tumour invasion and metastasis; (2) to develop novel therapeutic targets; (3) to improve therapeutic efficacy by optimal combinations of radiotherapy, chemotherapy, targeted therapy, or immunotherapy; and (4) to develop novel biomarkers for the prediction of therapeutic efficacy and/or patient prognosis. Primary cancer types we are currently working on include, but not limit to, ocular cancer (eg, uveal melanoma and retinoblastoma), brain tumour (eg, glioblastoma), gastrointestinal tumour (eg, gastric, colorectal and hepatic cancer), and head & neck cancer (eg, nasopharyngeal carcinoma). We are extremely keen to work together with people who have a great passions on pursuing a splendid scientific career in molecular, stratified and translational oncology. Enquiries with CV welcome to contact for details (Email: jlilab1971@163.com).

代表論文

1. Li JL and Harris AL.: The potential of new tumor endothelium-specific markers for the development of anti-vascular therapy. Cancer Cell, 2007;11(6):478-482 (通信作者). (5 year IF = 26.809).

2. Li JL and Harris AL.: Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell, 2006; 8(1): 1-4 (通信作者) (5 year IF = 26.809).

3. Masiero  M, Sim?es FC, Han HD, Snell C, Peterkin T, Bridges E, Li D, Han C, Tuynman JB, Mortensen N,  Li JL, et al.: A core human primary tumor angiogenesis signature identifies ELTD1, an endothelial orphan receptor regulating angiogenesis. Cancer Cell, 2013; 24(2): 229-241 (5 year IF = 26.809).

4. Favaro E, Bensaad K, Chong M, Tennant D, Ferguson D, Snell C, Steers G, Turley H, Li JL, et al.: Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metabolism, 2012; 16(6): 751-764 (5 year IF = 22.787).

5. Wang S, Huang X, Li Y, Lao H, Zhang Y, Dong H, Xu W, Li JL and Li M.: RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology, 2012; 53(6): 1932-1942 (通信作者) (IF = 14.971).

6. Cai L, Ye Y, Jiang Q, Lyu XM, Chen Y, Li JB, Wang S, Liu T, Yao KT, Li JL and Li X.:  Epstein-Barr Virus-encoded microRNA BART1 impels tumor metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nature Commun, 2015; 6: 7353 (通信作者) (5 year IF = 13.811).

7. Li JL, Sanson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridge, E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R and Harris AL.: DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Research, 2011; 71(18):6073-6083 (通信作者) (5 year IF = 9.062).

8. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA and Harris AL.: Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function and promotes tumor growth in vivo. Cancer Research, 2007; 67(23): 11244-11253 (通信作者) (5 year IF = 9.062).

9. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW and Harris AL.: Upregulation of delta-like 4 ligand in human tumour vasculature and the role of basal expression in endothelial cell function. Cancer Research, 2006; 65(19): 8690-8697 (通信作者) (5 year IF = 9.062).

10. Wang S, Wang X, Gao Y, Peng Y, Dong N, Zhang X, Wu Y, Li M and Li JL.:  RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway. The Journal of Pathology, 2019; 248(2): 204-216 (通信作者) (5 year IF = 6.424).